These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23613984)

  • 1. Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology.
    O'Meara CP; Armitage CW; Harvie MC; Timms P; Lycke NY; Beagley KW
    PLoS One; 2013; 8(4):e61962. PubMed ID: 23613984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection.
    Skelding KA; Hickey DK; Horvat JC; Bao S; Roberts KG; Finnie JM; Hansbro PM; Beagley KW
    Vaccine; 2006 Jan; 24(3):355-66. PubMed ID: 16153755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunity against a Chlamydia infection and disease may be determined by a balance of IL-17 signaling.
    O'Meara CP; Armitage CW; Harvie MC; Andrew DW; Timms P; Lycke NY; Beagley KW
    Immunol Cell Biol; 2014 Mar; 92(3):287-97. PubMed ID: 24366518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The duration of Chlamydia muridarum genital tract infection and associated chronic pathological changes are reduced in IL-17 knockout mice but protection is not increased further by immunization.
    Andrew DW; Cochrane M; Schripsema JH; Ramsey KH; Dando SJ; O'Meara CP; Timms P; Beagley KW
    PLoS One; 2013; 8(9):e76664. PubMed ID: 24073293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial protection against chlamydial reproductive tract infection by a recombinant major outer membrane protein/CpG/cholera toxin intranasal vaccine in the guinea pig Chlamydia caviae model.
    Andrew DW; Hafner LM; Beagley KW; Timms P
    J Reprod Immunol; 2011 Sep; 91(1-2):9-16. PubMed ID: 21856018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge.
    Pal S; Davis HL; Peterson EM; de la Maza LM
    Infect Immun; 2002 Sep; 70(9):4812-7. PubMed ID: 12183524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
    Yu H; Jiang X; Shen C; Karunakaran KP; Jiang J; Rosin NL; Brunham RC
    Infect Immun; 2010 May; 78(5):2272-82. PubMed ID: 20231405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge.
    Pal S; Tatarenkova OV; de la Maza LM
    Immunology; 2015 Nov; 146(3):432-43. PubMed ID: 26423798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.
    Murthy AK; Chambers JP; Meier PA; Zhong G; Arulanandam BP
    Infect Immun; 2007 Feb; 75(2):666-76. PubMed ID: 17118987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach.
    Li W; Guentzel MN; Seshu J; Zhong G; Murthy AK; Arulanandam BP
    Clin Vaccine Immunol; 2007 Dec; 14(12):1537-44. PubMed ID: 17942608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2010 Feb; 28(7):1668-72. PubMed ID: 20026449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.
    Cheng C; Pal S; Tifrea D; Jia Z; de la Maza LM
    Microbes Infect; 2014 Mar; 16(3):244-52. PubMed ID: 24291713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge.
    Pal S; Tifrea DF; Follmann F; Andersen P; de la Maza LM
    Vaccine; 2017 Mar; 35(13):1705-1711. PubMed ID: 28238632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal vaccination with Chlamydia pneumoniae induces cross-species immunity against genital Chlamydia muridarum challenge in mice.
    Manam S; Chaganty BK; Evani SJ; Zafiratos MT; Ramasubramanian AK; Arulanandam BP; Murthy AK
    PLoS One; 2013; 8(5):e64917. PubMed ID: 23741420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model.
    Hansen J; Jensen KT; Follmann F; Agger EM; Theisen M; Andersen P
    J Infect Dis; 2008 Sep; 198(5):758-67. PubMed ID: 18652549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection.
    Berry LJ; Hickey DK; Skelding KA; Bao S; Rendina AM; Hansbro PM; Gockel CM; Beagley KW
    Infect Immun; 2004 Feb; 72(2):1019-28. PubMed ID: 14742549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multistage vaccines containing outer membrane, type III secretion system and inclusion membrane proteins protects against a Chlamydia genital tract infection and pathology.
    O'Meara CP; Armitage CW; Andrew DW; Kollipara A; Lycke NY; Potter AA; Gerdts V; Petrovsky N; Beagley KW
    Vaccine; 2017 Jul; 35(31):3883-3888. PubMed ID: 28602608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization of a wild koala population with a recombinant Chlamydia pecorum Major Outer Membrane Protein (MOMP) or Polymorphic Membrane Protein (PMP) based vaccine: New insights into immune response, protection and clearance.
    Desclozeaux M; Robbins A; Jelocnik M; Khan SA; Hanger J; Gerdts V; Potter A; Polkinghorne A; Timms P
    PLoS One; 2017; 12(6):e0178786. PubMed ID: 28575080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge.
    Pal S; Theodor I; Peterson EM; de la Maza LM
    Infect Immun; 2001 Oct; 69(10):6240-7. PubMed ID: 11553566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.